ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Methimazole-induced cholestasis initially obscured by an incidental finding of a large periampullary diverticulum: A case report with reference to the updated RUCAM of 2016.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RUCAM-ascertained immunology and autoimmunity specifics of six idiosyncratic drug-induced liver injury types with refined classification: their individual complex molecular interplay.Frontiers in immunology · 2026Review
- Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methimazole is a commonly prescribed drug for hyperthyroidism and is generally well-tolerated, with complications occurring in less than 10% of treated patients. To our knowledge, there are approximately 30 reported cases of drug-induced liver injury (DILI) associated with the use of methimazole in the literature. DILI is a challenging diagnosis and can often mimic many forms of acute and chronic hepatitis. The pattern of liver injury can be hepatocellular, cholestatic, or mixed in nature. The R-value is a useful tool for characterizing the pattern of liver injury, while the Roussel Uclaf Causality Assessment Method (RUCAM) aids with quantifying the likelihood of DILI. The updated version of RUCAM from 2016 was used in this report. We present a case of a 72-year-old female who developed cholestatic DILI secondary to methimazole with a calculated RUCAM score of 8, initially obscured by both imaging and endoscopic findings concerning for hepatobiliary obstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.